

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

DUPLICATE



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>A61K 49/00, 47/48</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/21382</b>  <b>(43) International Publication Date:</b> 10 December 1992 (10.12.92)									
<b>(21) International Application Number:</b> PCT/EP92/01327 <b>(22) International Filing Date:</b> 3 June 1992 (03.06.92)  <b>(30) Priority data:</b> <table border="0"> <tr> <td>9111890.1</td> <td>3 June 1991 (03.06.91)</td> <td>GB</td> </tr> <tr> <td>9114570.6</td> <td>5 July 1991 (05.07.91)</td> <td>GB</td> </tr> <tr> <td>9200409.2</td> <td>9 January 1992 (09.01.92)</td> <td>GB</td> </tr> </table> <b>(71) Applicant (for GB only):</b> HOLMES, Michael, John [GB/GB]; Frant B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).  <b>(71) Applicant (for all designated States except US):</b> NYCOMED AS [NO/NO]; Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo 4 (NO).		9111890.1	3 June 1991 (03.06.91)	GB	9114570.6	5 July 1991 (05.07.91)	GB	9200409.2	9 January 1992 (09.01.92)	GB	<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> KLAVENESS, Jo [NO/NO]; Skøyen terrasse 15, N-0276 Oslo (NO). RONGVED, Pål [NO/NO]; Hovdens vei 13, N-1454 Hellvik (NO). STRANDE, Per [NO/NO]; Nordengveien 78A, N-0755 Oslo (NO).  <b>(74) Common Representatives:</b> HOLMES, Michael, John et al.; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), NO, SE (European patent), US.  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
9111890.1	3 June 1991 (03.06.91)	GB									
9114570.6	5 July 1991 (05.07.91)	GB									
9200409.2	9 January 1992 (09.01.92)	GB									
<b>(54) Title: IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS</b>  <b>(57) Abstract</b>  <p>Ultrasound contrast agents in the form of microparticles comprising a biotolerable matrix (e.g. of a carbohydrate or an X-ray contrast agent) in association with a gas or a precursor therefor are stabilised to enhance their <i>in vivo</i> stability and/or echogenicity by covalently modifying the structure of the matrix, e.g. to introduce crosslinking groups or to attach lipophilic groups and/or molecules. The covalent moieties may include biodegradable linkages to assist rapid subsequent elimination of the contrast agents from the system.</p>											

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

- 1 -

"Improvements in or relating to contrast agents"

5           This invention relates to novel contrast agents,  
more particularly to new microparticulate contrast  
agents of use in diagnostic ultrasonic imaging.

10           It is well known that ultrasonic imaging comprises  
a potentially valuable diagnostic tool, for example in  
studies of the vascular system, particularly in  
cardiography, and of tissue microvasculature. A variety  
of contrast agents has been proposed to enhance the  
acoustic images so obtained, including suspensions of  
15   solid particles, emulsified liquid droplets, gas  
microbubbles and encapsulated gases or liquids. It is  
generally accepted that low density contrast agents  
which are easily compressible are particularly efficient  
in terms of the acoustic backscatter they generate, and  
20   considerable interest has therefore been shown in the  
preparation of gas-containing and gas-generating  
systems.

          Initial studies involving free gas microbubbles  
25   generated in vivo by intracardiac injection of  
physiologically acceptable substances have demonstrated  
the potential efficiency of such bubbles as contrast  
agents in echocardiography; such techniques are severely  
limited in practice, however, by the short lifetime of  
30   the free bubbles. Interest has accordingly been shown  
in methods of generating and/or stabilising gas  
microbubbles for echocardiography and other ultrasonic  
studies, for example using emulsifiers, oils, thickeners  
or sugars.

35

          Techniques involving the use of sugars in  
ultrasound contrast agents are described in, for

- 2 -

example, US-A-4,681,119, US-A-4,442,843 and US-A-4,657,756, which disclose the use of particulate solids having a plurality of gas-filled voids and preferably also a plurality of nuclei for microbubble formation.

5 EP-A-0322350, WO 88/03388, EP-A-0123235, EP-A-0122624 and DE-A-3834705 suggest ultrasound contrast agents consisting of fatty acid-coated, gas-containing microparticles which may include sugars such as cyclodextrins, monosaccharides, disaccharides or

10 trisaccharides. US-A-4,832,941 claims ultrasound contrast agents consisting of a mixture of three components:- (1) macromolecules such as polysaccharides, (2) vegetable oil and (3) soluble iron (III) salts. EP-A-0077752 suggests ultrasound contrast agents consisting

15 of gas bubbles, surface active compounds (including fatty acid salts and derivatives) and viscosity increasing substances (including mono- or polysaccharides). EP-A-0327490 describes gas-containing amylose particles coated with polymers.

20

Schlieff, R. in International Symposium on Contrast Media, Tokyo (1988), pp. 323-328 gives an overview of ultrasound contrast media with focus on SHU 454 (Echovist ®), which is a saccharide-based product under

25 development by Schering AG. The same author in Contrast Media from past to the Future, symp. Berlin (1987), pp. 179-187 describes SHU 454 further. Loughery, E.J. et al. in Echocardiography (Elsevier) (1990), pp. 279-292 have published a review on study of circulation by

30 myocardial contrast echocardiography with focus on SHU 454, SHU 508 (Levovist ®) and the protein-based Albunex •.

Schlieff, R. in Radiology (1991) 178, pp. 213-215

35 has described clinical use of SHU 454 in hysterosalpingo-contrast sonography of the uterus and fallopian tubes. SHU 454 has also been described in the

- 3 -

- following publications: Rovai, D. et al., Circulation Supplement III (1990) 82, p. 26; Barzilai, B. et al., Circulation Supplement III (1990) 82, p. 96; Vorwerk, D. et al., Ultraschall in Med. (1990) 11, pp. 146-149; Von
- 5 Bibra, H. et al., Eur. Heart J. (1990) 11, p. s 112; Wilkenshoff, U. et al., Eur. Heart J. (1990) 11, p. s 113; El Mouaaouy, A. et al., Surg. Endosc. (1990) 4, pp. 114-117; Smith M.D. et al., JACC (1984) 3, pp. 992-998; Lange, L. et al., Arzneim.-Forsch./Drug Res. (1986)
- 10 36(II), pp. 1037-1040; Fritzsche, Th. et al., Invest. Radiol. (1988) 23 (Suppl 1), pp. 302-305; Arisawa, J. et al., International Symposium on Contrast Media, Tokyo (1988), pp. 331-332; Rovai, D. et al., JACC (1987) 10, pp. 125-134; Heidelmeyer, C.F. et al., J. Cardiothoracic
- 15 Anesthesia (1990) 4, pp. 60-67; Grube, E. et al., Z. Kardiol. (1986) 75, pp. 335-362; Meyer-Schwickerath et al., Ultraschall (1986) 7, pp. 34-36; and Becher, H. et al., Am. J. Cardiol. (1989) 64, pp. 374-377.
- 20 SHU 508 has been described in the following publications:
- Schlieff, R. et al., Circulation Supplement III (1990) 82, p. 28; Scharf, M. et al., Circulation Supplement III (1990) 82, p. 261; Fritzsche, T. et al., Invest.
- 25 Radiol. (1990) 25 (Suppl), pp. 160-161; Schlieff, R. et al., Echocardiography (1990) 7, pp. 61-64; and Smith, M.D. et al., JACC (1989) 13, pp. 1622-1628.

Aqueous suspensions of methylcellulose have been

30 evaluated as oral ultrasound contrast agents by Warren, P.S. et al. in J. Clin. Ultrasound (1978) 6, pp. 315-320.

Microbubbles encapsulated with calcium alginate

35 hav recently been described as a potential ultrasound contrast agent by Wheatley, M.A. et al. in Biomaterials (1990) 11, pp. 713-717 and Polymeric Materials Science

- 4 -

and Engineering (1990) 63, pp. 144-147.

5 A general disadvantage of existing particulate  
ultrasound contrast agents such as the sugar-based  
agents discussed above is their relative lack of  
stability in vivo. This is a particular problem in  
applications such as echocardiography, where there is a  
need for improved contrast agents combining sufficient  
stability and small microbubble size (typically less  
10 than about 10  $\mu\text{m}$ , preferably less than about 7  $\mu\text{m}$ ) to  
permit passage through the pulmonary capillary bed and  
so allow enhanced visualisation of the left side of the  
heart, preferably for more than one passage of  
circulation.

15 The present invention is based on our finding that  
the in vivo stability and/or the echogenicity of  
microparticulate ultrasound contrast agents may be  
substantially enhanced by covalently modifying the  
20 structure of the microparticulate matrix, for example to  
introduce stabilising crosslinking groups or a  
lipophilic coating. The covalently bound stabilising  
moieties may furthermore be chosen to include  
biodegradable linkages, so that the contrast agents  
25 exhibit the important property of being rapidly  
eliminatable from the subject in a short term after use,  
e.g. preferably having a half life of not more than 48  
hours in vivo, for example 1-12 hours.

30 Thus, according to one aspect of the present  
invention, there are provided ultrasound contrast agents  
in the form of microparticles comprising a biotolerable  
matrix in association with a gas or a precursor  
therefor, characterised in that the microparticles are  
35 stabilised by covalent bonding of the matrix.

- 5 -

It will be appreciated that the material of the biotolerable matrix must carry appropriate functional groups capable of reacting covalently with, for example, reagents such as crosslinking agents (including so-called zero-crosslinking agents) and/or reactive derivatives of lipids, e.g. as described in greater detail hereinafter. Subject to this requirement a wide range of biotolerable materials may be used in accordance with the invention, examples including

carbohydrates (for example hexoses such as glucose, fructose or galactose; disaccharides such as sucrose, lactose or maltose; pentoses such as arabinose, xylose or ribose;  $\alpha$ -,  $\beta$ - and  $\gamma$ - cyclodextrins; polysaccharides such as starch, hydroxyethyl starch, hydroxypropyl starch, amylose, amylopectin, glycogen, inulin, pulullan, dextran, carboxymethyl dextran, dextran phosphate, ketodextran or an alginate; and carbohydrates containing amino or amido groups, such as aminoethyl dextran, chitin, chitosan, hyaluronic acid or heparin - the term "carbohydrate" as used herein is also intended to embrace sugar alcohols, e.g. alditols such as mannitol or sorbitol); imaging agents (for example X-ray contrast agents such as any of the commercially available carboxylic acid and non-ionic amide X-ray contrast agents typically containing at least one 2,4,6-triiodophenyl group having at the 3- and/or 5- positions substituents such as carboxyl, carbamoyl, N-alkylcarbamoyl, N-hydroxyalkylcarbamoyl, acylamino, N-alkylacylamino or acylaminomethyl, as in metrizoic acid, diatrizoic acid, iothalamic acid, ioxaglic acid, iothexol, iopentol, iopamidol, iodixanol, iopromide, metrizamide, iodipamide, meglumine iodipamide, meglumine acetrizoate or meglumine diatrizoate); and polypeptides and proteins (e.g. gelatin or albumin such as human serum albumin).

Examples of contrast agents according to the invention include suspensions and solutions of



- 6 -

biotolerable microparticles which have gas present as an inclusion in the voids of their crystal structure and/or adhered to their surface; and microbubbles encapsulated by biotolerable materials, for example insoluble polysaccharides such as calcium alginate.

In one embodiment of the invention the microparticulate biotolerable matrix is presented in the form of aggregates (for example having an aggregate size of 20-125 micrometres, such as 30-50 micrometres) of particles having a particle size of, for example, 1-50 micrometres, such as 5-10 micrometres. Such aggregates, which may be prepared by, for example, conventional micronisation techniques such as grinding or milling, e.g. by ball-milling, will tend to contain a substantial volume of air adsorbed on their surfaces and entrained in voids such as interparticle cavities or at grain boundaries between the crystallites. The particle size may, for example, be selected to be substantially commensurate with the desired microbubble size. In applications such as echocardiography this will typically be less than about 10 micrometres to permit passage through the pulmonary capillary bed and so allow enhanced ultrasound visualisation of the left side of the heart, preferably for more than one passage of circulation.

Stabilisation in accordance with the invention may, for example, be effected by covalently crosslinking the biotolerable matrix, before, during or after inclusion of any gas or gas precursor, using a crosslinking agent having at least two functional groupings able to react with functional groupings present in the biotolerable matrix. Numerous such pairs of interacting functional groups are known in the art, e.g. as described by Baumert et al. in "Crosslinking techniques" (Meth.

- 7 -

Enzymol. 172 (1989), pp. 584-609) or in the Pierce Handbook and General Catalogue (1989), pp. 284-311.

Thus, for example, hydroxyl groups in biotolerable matrices such as carbohydrates may be crosslinked as described in "Advances in Carbohydrate Chemistry and Biochemistry" ed. by R. Stuart Tipson and D. Horton, (1976) vol. 33, pp. 11-109 (Academic Press, New York). Examples of appropriate functional groupings for this purpose include halogen atoms such as chlorine or bromine, e.g. in the form of acyl halides such as alkanoyl or sulphonyl halides; sulphonate ester groups, e.g. alkyl sulphonate esters such as mesyloxy groups and aromatic sulphonate esters such as tosyloxy groups;  $\alpha$ -halomethyl ester and keto groups; activated carboxyl groups, e.g. symmetrical or mixed anhydrides; activated hydroxyl groups; activated alkenes, e.g.  $\alpha,\beta$ -unsaturated ketones, amides and esters, e.g. acrylate and methacrylate esters; conjugated diyne and enyne systems; epoxy groups; and acetal-forming aldehyde and ketone groups and derivatives thereof such as enol ethers or acetal or ketal groups. Examples of crosslinking agents useful for stabilising carbohydrate matrices include epichlorohydrin (e.g. as described by Kartha, K.P.R. et al. in Staerke (1985) 37, pp. 297-306) and other epoxide derivatives (e.g. as described in US-A-4,126,669) and sodium trimetaphosphate (e.g. as described in WO 89/03674).

Biotolerable matrices containing carboxyl groups may, for example, be crosslinked by reaction with functional groups such as hydroxyl, mercapto, amino or diazo.

Crosslinking agents for use with proteinaceous or other biotolerable amino group-containing matrices include, for example, aldehydes, compounds containing

- 8 -

activated carboxyl groups such as N-hydroxysuccinimidyl, imidoesters, nitroaryl halides, compounds containing nitrene precursor groups such as phenylazido, carbene precursors (e.g. diazo compounds and diazirines),  
5 ketones, isocyanates, isothiocyanates, semicarbazides and thiosemicarbazides, epoxides, phenol esters (e.g. nitrophenol esters), acyl azides and hydrazines, haloformates, and acyl halides (e.g. alkanoyl chlorides or sulphonyl chlorides such as mesyl or tosyl chloride).  
10 Dialdehydes are a preferred class of crosslinking agent for use with proteinaceous matrices.


Sulfhydryl groups may, for example, be reacted with functional groups such as maleimides, sulphonated maleimides,  $\alpha$ -halomethyl carbonyl derivatives (e.g.  
15 esters, amides or ketones), alkyl or aralkyl halides, nitrosoureas, s-triazines, aziridines and pyridyl disulphides.

As indicated above, zero-crosslinking agents may also be employed. Thus, for example, aminoacid-  
20 containing substrates may be treated with condensing agents (e.g. a carbodiimide such as dicyclohexyl carbodiimide) to promote intramolecular reaction of the carboxyl and amino groups to form amide groups.


Crosslinking agents may be chosen so as to contain  
25 or form with the biotolerable matrix one or more biodegradable bonds having an appropriate degree of stability, particularly in cases where the matrix itself is not readily biodegradable. Suitable biodegradable linkages include, for example, amide,  
30 imide, imine, ester, anhydride, acetal, carbamate, carbonate, carbonate ester and disulphide groups. At least one such group may advantageously be present in the crosslinking grouping. In general, any esters will be biodegradable, particularly those containing the  
35 grouping  $-CO.O-$  or  $-O.CO.O-$ .

One particularly useful class of biodegradable ester groupings, which exhibits hydrolytic stability comparable to a traditional aliphatic ester but is highly cleavable enzymically in vivo has the structure

- 9 -



[in which each X, which may be the same or different, is selected from -O-, -S- and -NR-, where R represents a hydrogen atom or an organic group; each Y, which may be the same or different, represents carbonyl, thiocarbonyl, sulphonyl or phosphoryl (i.e. a group of formula



where  $R^3$  is a hydrogen atom or an organic group) or a similar acid-forming group; each Z, which may be the same or different, is selected from -O-, -S- and -NR-, where R represents a hydrogen atom or an organic group; m and n, which may be the same or different, are each zero or 1; and  $R^1$  and  $R^2$ , which may be the same or different, are each selected from hydrogen atoms, monovalent organic groups and groups of formula -X.Y.(Z)<sub>m</sub>- as hereinbefore defined, or  $R^1$  and  $R^2$  together form a divalent group].

Organic groups represented by R,  $R^1$ ,  $R^2$  and  $R^3$  may, for example, each be a hydrocarbyl or heterocyclic group, for example having 1-20 carbon atoms, e.g. an aliphatic group such as an alkyl or alkenyl group (preferably having up to 10 carbon atoms), a cycloalkyl

- 10 -

group (preferably having up to 10 carbon atoms), an  
araliphatic group such as an aralkyl group (preferably  
having up to 20 carbon atoms), an aryl group (preferably  
having up to 20 carbon atoms) or a heterocyclic group  
5 having up to 20 carbon atoms and one or more heteroatoms  
selected from O, S and N; such a hydrocarbyl or  
heterocyclic grouping may carry one or more substituents  
such as halogen atoms or groups of the formulae  $-NR^4R^5$ ,  
 $-CONR^4R^5$ ,  $-OR^6$ ,  $-SR^6$  and  $-COOR^7$  (where  $R^4$  and  $R^5$ , which may be  
10 the same or different, are hydrogen atoms, acyl groups  
or hydrocarbyl groups as defined for R,  $R^1$ ,  $R^2$  and  $R^3$ ;  $R^6$   
is a hydrogen atom or an acyl group or a group as  
defined for R,  $R^1$ ,  $R^2$  and  $R^3$ ; and  $R^7$  is a hydrogen atom or  
a group as defined for R,  $R^1$ ,  $R^2$  and  $R^3$ ). Where  $R^1$  and  $R^2$   
15 represent a divalent grouping, this may be an alkylene,  
alkenylene, alkylidene or alkenylidene group (preferably  
having up to 10 carbon atoms) which may carry one or  
more substituents as defined above. In general R,  $R^1$ ,  $R^2$   
and  $R^3$  are preferably H or small groups such as  $C_{1-4}$  alkyl  
20 groups.

Aliphatic groups R,  $R^1$ ,  $R^2$  and  $R^3$  may be straight or  
branched, saturated or unsaturated, and include, for  
example, alkyl and alkenyl groups such as methyl, ethyl,  
25 isopropyl, butyl and allyl. Araliphatic groups include  
(monocarbocyclic aryl) alkyl groups such as benzyl.  
Aryl groups include mono- and bi-cyclic groups such as  
phenyl, tolyl and naphthyl. Heterocyclic groups include  
5- and 6-membered rings preferably containing a single  
30 heteroatom, such as furyl, thienyl and pyridyl.

Possible substituents in hydrocarbyl groups R,  $R^1$ ,  $R^2$   
and  $R^3$  include hydroxyl, etherified hydroxyl (e.g.  $C_{1-5}$   
alkoxy such as methoxy), esterified hydroxyl (e.g.  $C_{1-6}$   
35 acyloxy such as acetoxy), etherified thiol, N-( $C_{1-6}$   
alkyl)amino, N-( $C_{1-6}$  acyl)amino, N-( $C_{1-6}$  acyl)-N-( $C_{1-6}$

- 11 -

alkyl)amino, carbamoyl, N-(C<sub>1-6</sub> alkyl) carbamoyl and halogen. Aromatic rings may carry C<sub>1-6</sub> alkyl groups, e.g. as in tolyl groups. Substituents may be present in combination and thus, for example, N-acyl and N-alkyl groups may carry hydroxyl or etherified or esterified hydroxyl groups.

Suitable crosslinking agents for stabilising biotolerable matrices in accordance with the invention include compounds of the formula

10

A-M-B

where M is a crosslinking divalent grouping and the groups A and B, which may be the same or different, optionally in conjunction with the groups to which they are attached, are functional groupings reactive with the biotolerable matrix, e.g. as hereinbefore described.

15

The group M may carry further groups reactive with the matrix to provide an even greater degree of crosslinking.

Preferably, the group M should not have a chain length of more than 50, more preferably not more than 30 atoms, and may, for example, be an alkylene or alkenylene group (e.g. containing up to 30, for example up to 10 carbon atoms, such as methylene or ethylene), a cycloalkylene group (e.g. containing up to 30, for example up to 10 carbon atoms), an arylene group (e.g. containing up to 30, for example up to 30 for example up to 20, carbon atoms), an aralkylene group (e.g. containing up to 20 carbon atoms) or a heterocyclic group (e.g. containing up to 30, for example up to 30, for example up to 20 carbon atoms and at least one heteroatom selected from O, N and S).

30

Biodegradable groups M may, for example, be of the form

35


$$-R^8-E-R^9-$$

where R<sup>8</sup> and R<sup>9</sup>, which may be the same or different, represent divalent organic groups optionally interrupted

- 12 -


by one or more heteroatoms and/or carrying one or more substituents containing such heteroatoms (e.g. carrying groups reactive with the matrix and/or further inert groups), and the group E is an ester grouping, for example of the formula  
 -O.CO-, or -O.CO.O-, or a diester or diamide group of formula (I) as defined above.

One useful class of crosslinking agents may be represented by the formula




(wherein A, B, R<sup>8</sup>, R<sup>9</sup>, X, Y, Z, m and n are as hereinbefore defined; R<sup>1a</sup> and R<sup>2a</sup> are as defined for R<sup>1</sup> and R<sup>2</sup> except that they may represent groups -X.Y.(Z)<sub>m</sub>.R<sup>8</sup>.A or -X.Y.(Z)<sub>n</sub>.R<sup>9</sup>.B rather than groups -X.Y.(Z)<sub>m</sub>-.

A second useful class of crosslinking agents may be represented by the formula



(wherein X, Y, Z, m, R<sup>1a</sup>, R<sup>2a</sup>, R<sup>8</sup> and A have the above-defined meanings and L is a leaving group). Such compounds may be reacted with compounds of the formula



- 13 -

(where X,Y,Z and n are as hereinbefore defined and  $R^{10}$  represents a hydrogen atom or an organic group), or appropriate reactive derivatives thereof (e.g. alkali metal salts of compounds of formula (IV) which are acids), to generate a biodegradable linkage of formula (I).

It will be appreciated that  $R^{10}$  may represent an organic group such that, for example, the compound (III) reacts to form a compound of formula (II) or a precursor therefor. Alternatively the group  $R^{10}$  may represent a substrate which is to be crosslinked; in addition to the  $-(Z)_n.Y.X.H$  substituent or reactive derivative thereof such a substrate will also possess a functional grouping reactive with  $-A$  or  $-R^8A$  in formula (III).


The divalent organic groups  $R^8$  and  $R^9$  in the above formulae may, for example, be selected from alkylene and alkenylene groups (e.g. containing up to 20, more preferably up to 10 carbon atoms), cycloalkylene groups (preferably having up to 10 carbon atoms), arylene groups (containing one or more aromatic rings and preferably having up to 20 carbon atoms), aralkylene groups (preferably having up to 20 carbon atoms and which may be bonded via the aryl and/or alkyl moieties - such aralkylene groups include, for example, two aryl groups joined by an alkylene chain), and heterocyclic groups (having one or more heteroatoms preferably selected from O, N and S and preferably having up to 20 carbon atoms). The groups may carry substituents, e.g. as set out above for  $R$ ,  $R^1$ ,  $R^2$  and  $R^3$  and/or substituents such as oxo or thio groups. The carbon chains may be interrupted by heteroatoms such as O, N, S or P, e.g. in conjunction with oxo substituents to form linkages such as ester, thioester or amide groups. The presence of disulphide linkages may also be advantageous by virtue of their inherent biodegradability.



- 14 -

It will be appreciated that groups  $R^8$  and/or  $R^9$  may be chosen so as to include one or more further groups of formula (I) and that the grouping  $-R^8.A$  in formula (III) may be such that it terminates in a grouping

5



10 (where  $X$ ,  $Y$ ,  $Z$ ,  $m$ ,  $R^{1a}$ ,  $R^{2a}$  and  $L$  are as hereinbefore defined) capable of generating a biodegradable linkage of formula (I).


15 Leaving groups  $L$  in compounds of formula (III) include halogen atoms such as chlorine or bromine and sulphonyloxy groups such as mesyloxy or tosyloxy.

20 Crosslinking agents of formulae (II) and (III) may be prepared by any convenient method. Thus, for example, one or two moles of a compound of formula



25 (where  $X$ ,  $Y$ ,  $Z$ ,  $m$ ,  $R^8$  and  $A$  are as hereinbefore defined, subject, if necessary and/or desired to  $A$  and any other reactive groups being protected), or a functional derivative thereof (e.g. a salt, for example an alkali metal salt such as the potassium or cesium salt of a compound (V) which is an acid), may be reacted with one


30 mole of a compound of formula



35


- 15 -

(where  $R^{1a}$ ,  $R^{2a}$  and L are as hereinbefore defined) to yield compounds of formula (III) and symmetrical compounds of formula (II) respectively. Alternatively, if an unsymmetrical compound of formula (II) is  
 5 required, one may, for example, react equimolar quantities of a compound of formula (V), or a functional derivative thereof, and a compound of formula



15 (where X, Y, Z, n,  $R^{1a}$ ,  $R^{2a}$ ,  $R^9$ , B and L are as hereinbefore defined, subject if necessary and/or desired to B and any other reactive groups being protected). Such reactions will normally be carried out in solution, for example in a polar solvent such as  
 20 dimethylformamide.

Symmetrical compounds of formula (II) in which  $R^{2a}$  represents a hydrogen atom, m and n are zero, each Y represents a carbonyl group and each X represents -O-  
 25 may also be prepared by reacting a compound of formula



(where A and  $R^8$  are as hereinbefore defined, subject, if  
 30 necessary and/or desired to A and any other reactive groups being protected) with an aldehyde of formula




35 (where  $R^{1a}$  is as hereinbefore defined) in the presence of an acid catalyst such as hydrochloric acid; if desired water may be removed from the reaction mixture by


- 16 -

azeotropic distillation.

Compounds of formula (III) in which L is a halogen atom may also be prepared by reaction of a compound of formula (V) as hereinbefore defined, particularly such a compound in which Y represents a carbonyl group and X represents -O-, with an aryl thioether of formula



(where  $R^{1a}$  and  $R^{2a}$  are as hereinbefore defined and  $R^{11}$  represents an aryl group such as phenyl), e.g. in a polar solvent such as dimethylformamide in the presence of a base such as pyridine, to yield a compound of formula




(wherein all the symbols are as hereinbefore defined) and halogenating this thioether, e.g. by reaction with sulfonyl chloride in a solvent such as dichloromethane or with bromine in a solvent such as carbon tetrachloride, to yield a compound (III) in which L is chlorine or bromine respectively.

Alternatively, compounds of formula (III) may be prepared by reaction of a compound of formula (V), as hereinbefore defined, with a chlorosulphate of formula

35

- 17 -



5

(wherein  $R^{1a}$ ,  $R^{2a}$ , and L are as hereinbefore defined, L preferably being chlorine), e.g. using the method of Binderup *et al.* described in Synth. Comm. 14(9) (1984), pp. 857-864.

10

Protecting groups used in connection with A and B and any other reactive groups present may, for example, be those conventional in the art. Thus, for example, carboxyl groups may be protected using reductively cleavable ester groups such as benzyl, and hydroxyl groups may be protected using acid cleavable etherifying groups such as triphenylmethyl.

15

One may also prepare compounds of formulae (II) and (III) containing precursors for the  $A.R^8-$  (and/or  $-R^9.B$  groups where appropriate) and subsequently convert such precursor groups to the desired reactive groupings. Thus, for example, compounds in which A and/or B represent epoxide groups may be prepared by oxidation of precursors containing appropriately positioned (e.g. terminal) ethylenically unsaturated bonds (e.g. using an oxidising agent such as metachloroperbenzoic acid), or by reacting compounds containing appropriately positioned hydroxyl groups (e.g. phenolic hydroxyl groups) with reagents such as epichlorohydrin; compounds in which  $A.R^8-$  and/or  $-R^9.B$  represent enol ether groups may be prepared by, for example, acid-catalysed elimination from corresponding acetals or ketals. Hydroxyl group-containing precursors may also be activated by, for example, reaction with sulphonyl halides such as mesyl or tosyl chloride to generate reactive leaving groups such as mesylate or tosylate or with  $\alpha,\beta$ -unsaturated alkenyl halides such as acryloyl

20

25

30


35

- 18 -


chloride to generate  $\alpha,\beta$ -unsaturated esters.

Compounds of formula (VII) in which L represents a halogen atom may, for example, be prepared by reacting compounds of formulae

5



10



15 (where Hal represents a halogen atom and the remaining symbols have the above-defined meanings), e.g. in the presence of a base such as pyridine.

The preparation of a range of crosslinking agents of formulae (II) and (III) is described in greater  
20 detail in our International Patent Application No. PCT/EP92/00717, the contents of which are incorporated herein by reference.

In a further embodiment of the invention the  
25 ultrasound contrast agents have lipophilic groups and/or molecules covalently attached to the biotolerable matrix, if desired in the form of a coating. Thus, for example, lipids may be covalently attached to products such as gas-containing particles of carbohydrates such  
30 as galactose, galactose/starch mixtures or xylose or X-ray contrast agents such as iohexol, iodixanol or metrizamide so as to increase their stability in a controllable manner, e.g. by decreasing their solubility.

35

Lipids useful for this purpose include derivatives of fatty acids (e.g. long chain alkanolic or alkenolic

- 19 -

acids preferably containing 10-50, .g. 10-30 carb n  
atoms, such as capric, palmitic, stearic, linolenic,  
behenic, docosanedioic or melissic acid), aralkanoic  
acids (e.g. phenyl lower alkanoic acids such as  
5 2-phenylbutyric acid), cholesterol derivatives (e.g.  
cholanic acids such as 5 $\beta$ -cholanic acid), and other  
biocompatible lipids possessing one or more functional  
groups, such as acid halide or anhydride groups or  
activated alkene groups covalently attachable to  
10 substituents such as hydroxyl groups. Thus, for  
example, surfactants such as poloxamers ("Pluronic")  
may be esterified to introduce an  $\alpha,\beta$ -unsaturated lower  
alkenoyl group such as an acryloyl group which will  
covalently react with hydroxyl groups present in  
15 biotolerable matrices such as carbohydrates.

The lipophilic groups and/or molecules may be such  
as also to act as crosslinking agents; such groups may  
be introduced by, for example, reaction with appropriate  
20 bi-or poly-functional lipid derivatives.

In addition to or alternatively to air, any  
biocompatible gas may be employed in the contrast agents  
of the invention, for example nitrogen, oxygen,  
25 hydrogen, nitrous oxide, carbon dioxide, helium, argon,  
sulphur hexafluoride and low molecular weight optionally  
fluorinated hydrocarbons such as methane, acetylene or  
carbon tetrafluoride. The term "gas" as used herein  
includes any substance in the gaseous form at 37°C. The  
30 gas may be contained in the contrast agent in such a way  
that before use the product is non-contrast giving but  
becomes effective on administration, e.g. as a result of  
the gas forming microbubbles as a soluble matrix  
dissolves. The rate of microbubble formation may thus  
35 b controlled by, for exampl , selecti n of an  
appropriat degree of crosslinking or lipid attachment.

- 20 -

Gas precursors useful in contrast agents according to the invention include carbonates and bicarbonates (e.g. sodium or ammonium bicarbonate) and aminomalonate esters.

5

For applications in echocardiography, in order to permit free passage through the pulmonary system and to achieve resonance with the preferred imaging frequency of about 0.1-15 MHz, it may be convenient to employ microbubbles and microparticles having an average size of 0.1-10  $\mu\text{m}$ , e.g. 1-7  $\mu\text{m}$ ; the use of microparticles of average size 1-2  $\mu\text{m}$  to generate microbubbles with an average size of 4-7  $\mu\text{m}$  is generally advantageous. Substantially larger bubbles and particles, e.g. with average sizes of up to 500  $\mu\text{m}$ , may however be useful in other applications, for example gastrointestinal imaging.

The following non-limitative Examples serve to illustrate the invention:-

#### Preparation 1

##### Milled D-(+)-galactose

20g of commercially available D-(+)-galactose (Reinst ph.Ned.Merck) was ball-milled in an aluminium ball-mill with 3 x 1.5 cm diameter aluminium balls for two hours. The resulting powder mixture consisted of crystals and aggregates of galactose in the particle size range of 1 - 100  $\mu\text{m}$  (measured by light scattering, Malvern Mastersizer).

#### Preparation 2

##### Milled D-(+)-galactose/starch

35

5g of commercially available D-(+)-galactose , (Reinst Ph.Ned, Merck) was mixed with 5g of commercially

- 21 -

available starch (Reppal PSM 70, Reppe glykos, Sweden) and ground in a stainless steel ball mill (Retsch centrifugal ball mill, S 1) with a 50 ml grinding cup and 3 x 20 mm balls for 10 minutes.

5

Preparation 3Milled xylose

10g of commercially available D-(+)-xylose (BHD) was ground in a stainless steel ball mill with a 50 ml grinding cup and 3 x 20 mm balls for 10 minutes.

Preparation 4

15 Palmitic acid carbonic acid monoisobutyl ester mixed anhydride

Palmitic acid (5.0 g, 19.5 mmol) was suspended in dry acetonitrile with triethylamine (1.97 g, 19.5 mmol) under nitrogen. The suspension became a thick slurry after stirring for 1 hour. Isobutyl chloroformate (2.66 g, 19.5 mmol) was added in one portion while cooling in an ice/water bath. After 30 min., the reaction was stirred overnight at room temperature. The resulting suspension was filtered, and the pink filtrate was evaporated to dryness at 30°C, yielding 7.8 g of a pink/white solid. <sup>13</sup>C-NMR confirmed the structure of the mixed anhydride.

Preparation 5

30 5- $\beta$ -Cholanic acid carbonic acid monoisobutylester mixed anhydride

5- $\beta$ -Cholanic acid (Sigma, 3.6 g, 10 mmol), was dissolved in diethyl ether (100 ml). Triethylamine (1.38 ml, 10 mmol) was added, and the reaction mixture was cooled to 0°C. Isobutyl chloroformate (1.37 g, 10 mmol) was added



- 22 -

dropwise with vigor us stirring over 2 minutes. After a voluminous precipitation, diethyl ether (100 ml) was added. Stirring was continued at 0° for 40 minutes; the icebath was removed and stirring was continued for  
5 another 60 minutes.

The precipitate was removed by filtration and the filtrate was transferred to an extraction funnel and extracted with saturated sodium bicarbonate (25 ml) and  
10 water (2 x 25 ml) and dried over MgSO<sub>4</sub>. The solvent was removed in vacuo, giving an 80% yield of a semisolid waxy substance. The product was characterised by <sup>13</sup>C-NMR:CO-acid:168.37 ppm, CO-carbonate:149.36 ppm.

15 Preparation 6

Melissic acid carbonic acid monoisobutyl ester mixed anhydride

Melissic acid (Sigma, 0.5 g, 1.1 mmol) was  
20 dissolved in diethyl ether (25 ml). Triethylamine (151 µl, 1.1 mmol) was added, and the reaction mixture was cooled to 0° C. Isobutyl chloroformate (151 µl, 1.1 mmol) was added dropwise with vigorous stirring over 2 minutes. The reaction mixture was treated as described  
25 in Preparation 5, and the product was characterised by <sup>13</sup>C-NMR:CO-acid:168.596 ppm, CO-carbonate:149.728 ppm.

Preparation 7

Docosanedioic acid bis(carbonic acid monoisobutyl ester mixed anhydride)  
30

Docosanedioic acid (Fluka, 1 g, 2.7 mmol), was dissolved in diethyl ether (25 ml). Triethylamine (747 µl, 2.7 mmol) was added and the reaction mixture was  
35 cooled to 0° C. Isobutyl chloroformate (743µl, 2.7 mmol) was added dropwise with vigorous stirring over 2 minutes. Th reaction mixture was treated as describ d

- 23 -

in Preparation 5, and the product was characterised by  $^{13}\text{C}$ -NMR: CO-acid:168.049 ppm, CO-carbonate: 149.359 ppm.

#### Preparation 8

##### 5 Bisacryloylpluronic F68

Pluronic F68 (Fluka, 8.35 g, 1 mmol) was dissolved in toluene (50 ml) and heated to 50° C under nitrogen. Triethylamine (1.4 ml, 10 mmol) was added. Acryloyl chloride (Fluka, 0.94 g, 10 mmol) in toluene (10 ml) was  
10 added over 10 minutes with stirring. Stirring was continued at 50° C; monitoring by TLC indicated full consumption of the starting material after 2 hours. The precipitate was removed by filtration and the filtrate  
15 was poured into diethyl ether (750 ml) with vigorous stirring. The precipitate was collected by filtration, redissolved in toluene (30 ml) with heating and added dropwise to a 1:1 mixture of diethyl ether and pentane (500 ml) with vigorous stirring. The resulting mixture  
20 was stored in a refrigerator overnight, whereafter the precipitated product was collected by filtration and dried under vacuum. Yield: 7g. The product was characterized by FT-IR:CO-1724  $\text{cm}^{-1}$ , disappearance of OH- at 3500  $\text{cm}^{-1}$ .

25

#### Example 1

##### Milled D-(+)-galactose covalently bonded to palmitic acid

30 A sealable 25 ml flask was loaded with 1.00 g of milled galactose prepared as described in Preparation 1 under nitrogen and to the flask was added 6 mg of palmitic acid carbonic acid monoisobutyl ester mixed anhydride prepared as described in Preparation 4  
35 dissolved in 10 ml dry methylene chloride under nitrogen. The sealed flask was shaken gently for 18 hours at ambient temperature. The solid content was

- 24 -

isolated by filtration, washed several times with methylene chloride, and dried over calcium chloride in a desiccator at 50 mbar and ambient temperature for 24 hours. The resulting product was a white solid with the same appearance as the starting material. Weight : about 1 g.

Examples 2-21

10 The procedure of Example 1 was repeated using the acid derivatives listed in Table 1 in the amount shown.

Table 1

15	<u>Example No.</u>	<u>Acid derivative</u>	<u>Amount</u> <u>(% w/w relative to</u> <u>galactose)</u>
20	2	Palmitic acid carbonic acid monoisobutyl ester mixed anhydride (Preparation 4)	0.2
	3	"	2
25	4	"	20
	5	2-Phenylbutyric acid anhydride (Fluka)	0.05
30	6	"	0.5
	7	Linolenic acid anhydride (Sigma)	0.05
35	8	"	0.5

- 25 -

	9	Stearic acid anhydride (Sigma)	0.05
	10	"	0.5
5	11	"	5
	12	Capric acid anhydride (Sigma)	0.05
10	13	"	0.5
	14	Behenic acid anhydride (Sigma)	0.05
15	15	"	0.5
	16	5 $\beta$ -Cholanic acid carbonic acid monoisobutyl ester mixed anhydride (Preparation 5)	0.1
20	17	"	1
	18	Melissic acid carbonic acid monoisobutyl ester mixed anhydride (Preparation 6)	0.1
25	19	"	0.2
	20	"	1
30	21	Docosanedioic acid bis(carbonic acid monoisobutyl ester mixed anhydride) (Preparation 7)	6
35			

- 26 -

Examples 22-24

Milled D-(+)-galactose/starch (1:1) prepared as described in Preparation 2 was reacted with the materials shown in Table 2 in the stated quantities, using the procedure of Example 1.

Table 2

Example No.	Acid derivative	Amount (% w/w relative to galactose)
22	Bis(acryloyl) pluronic F68 (Preparation 8)	0.1
23	"	1
24	Behenic acid anhydride (Sigma)	0.2

Example 25

Milled xylose prepared as described in Preparation 3 was reacted with 0.2% w/w of behenic acid anhydride (Sigma) using the procedure of Example 1.

Example 26

Reaction of dioleoylphosphatidylethanolamine (DOPE) with milled D-(+)-galactose

Milled D-(+)-galactose prepared as described in Preparation 1 (6.0 g) was suspended in dry acetone, and carbonyldiimidazole (Fluka, 7.32 g, 45.1 mmol) was added. After stirring for 30 minutes at ambient temperature, the solid was filtered off and washed with dry acetone (3 x 50 ml) on the filter. The solid was

- 27 -

resuspended in dry methylene chloride (50 ml), and a solution of diol oylphosphatidylethanolamin (provided by Hafslund Nycomed Pharma, Austria, 1.00 g, 1.43 mmol) in dry methylene chloride (30 ml) was added. The sealed  
5 reaction flask was shaken at ambient temperature for 72 hours. The solid was filtered off and washed on the filter with methylene chloride (3 x 50 ml). The slightly yellow solid (5.5 g) was kept in a desiccator over calcium chloride.

10

Example 276-O-Palmitoyl-D-galactopyranose

(A) 6-O-Palmitoyl-1,2,3,4-diisopropylidene-D-  
15 galactopyranose

1,2,3,4-Diisopropylidene-D-galactopyranose (Sigma, 13.4 g, 51.3 mmol) and triethylamine (7.15 ml, 51.3 mmol) were dissolved in methylene chloride (150 ml) and  
20 cooled to 0° C. Palmitoyl chloride (Aldrich, 14.1 g, 51.3 mmol) dissolved in methylene chloride (100 ml) was added dropwise with stirring over 1 h. The cooling bath was removed and the reaction mixture was stirred overnight. The precipitate was removed by filtration, the filtrate  
25 was transferred to a separating funnel and extracted with water (3 x 50 ml), dried over MgSO<sub>4</sub> and the solvent was removed in vacuo. The residue was a light brownish oil which solidified to waxy crystals. Crude yield: 23g. The crude product was used without further purification.  
30 A small aliquot was recrystallized for characterisation. FT-IR: CO-1734 cm<sup>-1</sup>. <sup>13</sup>C-NMR: CO-ester 172.79. Mp. 124-127°C.

(B) 6-O-Palmitoyl-D-galactopyranose

35

6-O-Palmitoyl-1,2,3,4-diisopropylidene-D-galactopyranose (6g) was dissolved in acetic acid (25

- 28 -

ml) and heated to 100°C under nitrogen for 6h. During subsequent cooling to room temperature, the product precipitated from the solvent, and was left at room temperature overnight. The crystals were collected by  
5 filtration and dried under vacuum. Yield: 3.3 g.  
The product was characterized by FT-IR: CO-1734 cm<sup>-1</sup>; OH-3464 cm<sup>-1</sup>.

#### Example 28

##### 10 6-O-Palmitoyl-D-galactopyranose/galactose mixtures

(A) D-(+)-galactose (2g) was dissolved in purified water (2.87g) and sterile filtered. 6-O-Palmitoyl-D-galactopyranose (0.25g) prepared as described in Example  
15 27 was dissolved in ethanol (3g) and sterile filtered. The solution of the palmitoyl-galactopyranose was added to the galactose solution under stirring and the whole mixture was taken to dryness under vacuum (10 torr, 50°C). The product was dried in a desiccator overnight.

20

(B) The procedure of (A) was repeated using 6-O-palmitoyl-D-galactopyranose (0.50g) dissolved in ethanol (6g).

#### 25 Example 29

##### Iohexol functionalised with palmitic acid

A sealable 25 ml flask was loaded with 1.00 g of Iohexol (NYCOMED), ball-milled as described in  
30 Preparation 1, under nitrogen. To the flask was added 35 mg of palmitic acid carbonic acid monoisobutyl ester mixed anhydride (prepared as described in Preparation 4) dissolved in 10 ml dry methylene chloride under  
nitrogen, and the sealed flask was shaken gently for 18  
35 hours at ambient temperature. The solid was isolated by filtration and washed several times with methylene chloride, and dried over calcium chloride in a

- 29 -

desiccator at 50 mbar and ambient temperatur for 24 hours. The resulting product was a white solid with the same appearance as the starting material. Weight: about 1 g. A sample of the product was added to water under a microscope, and a number of gas bubbles were observed.

EXAMPLE 30Iodixanol functionalised with palmitic acid

1.00 g of iodixanol, ball-milled as described in Preparation 1, was reacted with 12 mg of palmitic acid carbonic acid monoisobutyl ester mixed anhydride (prepared as described in Preparation 4) using the method of Example 29. About 1 g white solid with the same appearance as the starting material was recovered. As in Example 29, microscopy showed development of gas bubbles when the product was added to water.

EXAMPLE 31Metrizamide functionalised with palmitic acid

1.00 g of Amipaque, ball-milled as described in Preparation 1, was reacted with 15 mg of palmitic acid carbonic acid monoisobutyl ester mixed anhydride (prepared as described in Preparation 4) using the method of Example 29. About 1 g white solid with the same appearance as the starting material was recovered. Microscopy showed development of a plurality of gas bubbles when the product was added to water.

EXAMPLE 32D-(+)-Galactose crosslinked with methylene diacrylate(A) Methylene diacrylate

A solution of potassium hydroxide (1.00 M, 40.00 ml) was added to acrylic acid (2.88 g, 40.00 mmol) at 0°C, and the solution was freeze dried for 16 h. Dry



- 30 -

DMF (200ml) was added and the suspension heated to 60°C under a dry N<sub>2</sub> atmosphere. Diiodomethane (1.61 ml, 20.00 mmol) was added in two portions during 10 min., and the reaction mixture left for 4 days at 60°C. The solvent  
5 was removed under reduced pressure (0.05 mm Hg) and diethyl ether (140 ml), saturated aqueous sodium hydrogen carbonate (50 ml) and water (50 ml) were added. The aqueous layer was extracted with diethyl ether (6 x 60 ml), and the combined ether extracts washed with  
10 water (4 x 50 ml), dried (MgSO<sub>4</sub>) and evaporated to give 1.06g (34%) product. <sup>1</sup>H-NMR (60 MHz, CDCl<sub>3</sub>): 5.81-6.61 (2xCH<sub>2</sub>=CH-, m), 5.84 (CH<sub>2</sub>, s).

15 B) Milled D-(+)-galactose crosslinked with methylene diacrylate

A sealable 25 ml flask was loaded with 1.00g of milled D-(+)-galactose prepared as described in Preparation 1 under nitrogen and to the flask was added  
20 methylene diacrylate (500 mg) dissolved in dry methylene chloride (10 ml) under nitrogen. The sealed flask was shaken gently for 18 hours at ambient temperature. The solid content was isolated by filtration and washed  
25 several times with methylene chloride, and dried over calcium chloride in a dessicator at 5 mbar and ambient temperature for 24 hours. The resulting product was a white solid with the same appearance at the starting material. Weight : about 0.96g.

30 Example 33

D) Echogenicity in vitro

10 ml of propylene glycol mixed with 90 ml of 5% dextros in water was used as a carrier liquid for  
35 determining the echogenicity of products of the Examples. 1.0g of each product to be tested was dispersed in 3.0ml of the carrier liquid and shaken for

- 31 -

15 sec nds. The resulting mixture as added to 52ml of 5% human serum albumin infusion solution in the measurement cell and the acoustic effects of the products were investigated by measuring the acoustic transmission through the samples using a 5 MHz broadband transducer in a pulse-reflection technique. The temperature in the measurement cell was stabilised to 37°C and circulation of the liquid was maintained by means of stirring at a constant rate. Ultrasound transmission through the samples was measured as a function of time over a duration of 390 seconds. Results were normalised to measurements on a reference consisting of 55ml of 5% human serum albumin infusion solution.

15

Results for a number of the exemplified products and comparative results for unmodified milled D-(+)-galactose prepared as described in Preparation 1 are shown in the accompanying drawing. It will be apparent that the products of the invention exhibit a strong effect on ultrasonic attenuation in vitro, the effect persisting for several minutes.

20


Claims

1. Ultrasound contrast agents in the form of microparticles comprising a biotolerable matrix in association with a gas or a precursor therefor, characterised in that the microparticles are stabilised by covalent bonding of the matrix.
2. Ultrasound contrast agents as claimed in claim 1 in which the biotolerable matrix is a carbohydrate.
3. Ultrasound contrast agents as claimed in claim 2 in which the carbohydrate is galactose.
4. Ultrasound contrast agents as claimed in claim 1 in which the biotolerable matrix is an X-ray contrast agent.
5. Ultrasound contrast agents as claimed in any of the preceding claims in which the microparticles are present in the form of aggregates having an aggregate size of 30-50 micrometres of microparticles having a particle size of 5-10 micrometres.
6. Ultrasound contrast agents as claimed in claim 5 in which the said aggregates have been prepared by ball-milling.
7. Ultrasound contrast agents as claimed in any of the preceding claims in which the microparticles are stabilised by the presence of crosslinking groupings.
8. Ultrasound contrast agents as claimed in claim 7 in which the crosslinking groupings contain biodegradable linkages selected from amide, imide, imine, ester,

- 33 -

anhydride, acetal, carbamate, carbonate, carbonat st r  
and disulphide groups.

9. Ultrasound contrast agents as claimed in claim 8 in  
which the crosslinking groups contain biodegradable  
linkages of the formula (I)



(wherein each X, which may be the same or different, is  
selected from -O-, -S- and -NR-, where R represents a  
hydrogen atom or an organic group; each Y, which may be  
the same or different, represents carbonyl,  
thiocarbonyl, sulphonyl, phosphoryl or a similar acid-  
forming group; each Z, which may be the same or  
different, is selected from -O-, -S- and -NR-, where R  
is as defined above; m and n, which may be the same or  
different, are each zero or 1; and R<sup>1</sup> and R<sup>2</sup>, which may  
be the same or different, are each selected from  
hydrogen atoms, monovalent organic groups and groups of  
formula -X.Y.(Z)<sub>m</sub>- as hereinbefore defined, or R<sup>1</sup> and R<sup>2</sup>  
together form a divalent organic group).


10. Ultrasound contrast agents as claimed in any of  
claims 1 to 6 in which the microparticles are stabilised  
by having lipophilic groups and/or molecules covalently  
attached thereto.

11. Ultrasound contrast agents as claimed in claim 10  
in which the microparticles are stabilised by having  
covalently attached thereto lipophilic groups deriv d  
from a fatty acid, an aralkanoic acid or a cholest rol,  
poloxamer or phosph lipid derivative.

- 34 -

12. Ultrasound contrast agents as claimed in claim 11 in which the said lipophilic groups are derived from capric acid, palmitic acid, stearic acid, linolenic acid, behenic acid, docosanedioic acid, melissic acid, phenylbutyric acid, 5 $\beta$ -cholanic acid, bis(acryloyl)pluronic F68 or dioleoylphosphatidylethanolamine.

1/1



# INTERNATIONAL SEARCH REPORT

International Application No. **PCT/EP 92/01327**

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC <b>Int.Cl.5                      A 61 K 49/00                      A 61 K 47/48</b>		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
<b>Int.Cl.5</b>	<b>A 61 K</b>	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	EP,A,0052575 (ULTRA MED) 26 May 1982, see page 6, line 34 - page 7, line 33; page 10, lines 12-28; page 23, line 30 - page 24, line 10; page 27, lines 14-29; page 28, lines 12-32; page 41, line 9 (cited in the application) ---	1-6
P,Y	EP,A,0458745 (SINETICA) 27 November 1991, see column 9, lines 2-16; column 10, lines 17-25; column 11, lines 1-29; claims ---	1-12
X	---	1-6
P,Y	WO,A,9204392 (NYCOMED) 19 March 1992, see page 18, lines 7-17,35-39; claims ---	1-12
X	-/-	
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
22-09-1992	20. 10. 92	
International Searching Authority	Signature of Authorized Officer	
EUR PEAN PATENT OFFICE		

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category*	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	EP,A,0160266 (TERUMO K.K.) 6 November 1985, see page 4, lines 25-36; page 7, line 32 - page 8, line 6 ---	1,11,12
P,X	WO,A,9205806 (SINTETICA S.A.) 16 April 1992, see abstract ---	1,7
A	WO,A,8400294 (SCHRÖDER) 2 February 1984, see page 3, lines 15-20; page 4, lines 18-23 ---	1-12
X	EP,A,0327490 (SCHERING) 9 August 1989, see column 4, lines 42-49; claims (cited in the application) ---	1-12
Y	Biomaterials, vol. 11, no. 9, November 1990, (Guildford, Surrey, GB), M.A. WHEATLEY et al.: "Contrast agents for diagnostic ultrasound: development and evaluation of polymer-coated microbubbles", pages 713-717, see page 716 (cited in the application) ---	1-12
E	EP,A,0502814 (SINTETICA) 9 September 1992, see whole document ---	1-12
X	EP,A,0184899 (NYEGAARD & CO.) 18 June 1986, see claims -----	1-12



**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9201327  
SA 61450

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 14/10/92. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0052575	26-05-82	AU-B- 565842	01-10-87
		AU-A- 4127485	19-09-85
		AU-B- 545866	01-08-85
		AU-A- 7931382	07-06-82
		CA-A- 1170569	10-07-84
		WO-A- 8201642	27-05-82
		US-A- 4442843	17-04-84
		US-A- 4657756	14-04-87
		US-A- 4681119	21-07-87
EP-A- 0458745	27-11-91	AU-A- 7614491	21-11-91
		CN-A- 1056634	04-12-91
WO-A- 9204392	19-03-92	AU-A- 8525691	30-03-92
EP-A- 0160266	06-11-85	JP-B- 1009284	16-02-89
		JP-C- 1524139	12-10-89
		JP-A- 60231609	18-11-85
		DE-A- 3584850	23-01-92
WO-A- 9205806	16-04-92	AU-A- 8495891	28-04-92
		EP-A- 0504340	23-09-92
WO-A- 8400294	02-02-84	AU-B- 567434	19-11-87
		AU-A- 1776083	08-02-84
		DE-A- 3376797	07-07-88
		EP-A, B 0113749	25-07-84
		US-A- 4713249	15-12-87
EP-A- 0327490	09-08-89	DE-C- 3803971	07-09-89
		DE-A- 3803972	10-08-89
		AU-A- 3035189	25-08-89
		WO-A- 8906978	10-08-89
		EP-A- 0398935	28-11-90
		JP-T- 3503634	15-08-91
EP-A- 0502814	09-09-92	None	
EP-A- 0184899	18-06-86	SE-B- 465908	18-11-91

FORM P079

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9201327  
SA 61450

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 14/10/92. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0184899		SE-B- 465909	18-11-91
		JP-A- 61155338	15-07-86
		SE-A- 8405500	02-05-86
		US-A- 4985233	15-01-91
		SE-A- 8405501	02-05-86